Vir Biotechnology (VIR) Operating Expenses (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Operating Expenses data on file, last reported at $132.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 7.24% year-over-year to $132.3 million; the trailing twelve-month figure through Mar 2026 stood at $537.6 million (down 19.46% YoY), and the FY2025 full-year result was $547.9 million, down 17.16% from the prior year.
• Operating Expenses improved to $132.3 million in Q1 2026, from $112.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $233.7 million in Q3 2024 to a low of $112.0 million in Q4 2025.
• A 5-year average of $170.3 million and a median of $173.7 million in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 59.06% in 2022 and sank 33.86% in 2024, its largest moves.
• Tracing VIR's Operating Expenses over 5 years: stood at $199.9 million in 2022, then decreased by 22.06% to $155.8 million in 2023, then declined by 16.87% to $129.5 million in 2024, then fell by 13.54% to $112.0 million in 2025, then rose by 18.1% to $132.3 million in 2026.
• Business Quant data shows VIR's Operating Expenses at $132.3 million in Q1 2026, $112.0 million in Q4 2025, and $173.7 million in Q3 2025.